PAVmed
PAVM
55 hedge funds and large institutions have $3.78M invested in PAVmed in 2023 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 9 increasing their positions, 13 reducing their positions, and 6 closing their positions.
333% more call options, than puts
Call options by funds: $52K | Put options by funds: $12K
1% more capital invested
Capital invested by funds: $3.76M → $3.78M (+$24.8K)
0% less ownership
Funds ownership: 0.02% → 0.02% (-0%)
5% less funds holding
Funds holding: 58 → 55 (-3)
31% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 13
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Charles Schwab
San Francisco,
California
|
+$35.4K |
| 2 |
OIA
OneDigital Investment Advisors
Overland Park,
Kansas
|
+$15.4K |
| 3 |
LPL Financial
San Diego,
California
|
+$10.2K |
| 4 |
AC
Ayrton Capital
Westport,
Connecticut
|
+$8.6K |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
+$4.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Verition Fund Management
Greenwich,
Connecticut
|
-$122K |
| 2 |
BlackRock
New York
|
-$82K |
| 3 |
LCS
Levin Capital Strategies
New York
|
-$66.8K |
| 4 |
Millennium Management
New York
|
-$56.4K |
| 5 |
BAM
Belpointe Asset Management
Reno,
Nevada
|
-$35.6K |
PAVM Hedge Fund Activity: Q2 2023 in Review
55 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in PAVmed (PAVM) for Q2 2023, worth a combined $3.78M — up 0.66% from $3.76M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of PAVM and 3 opened new positions — a net loss of 3 holders — while 13 trimmed existing stakes and 9 added.
The largest buyer was Charles Schwab, opening a new position worth an estimated $35.4K. The largest seller was Verition Fund Management, cutting an estimated $122K.
- 55 institutional investors held PAVmed (PAVM) as of Q2 2023, down from 58 in Q1 2023.
- Funds reported $3.78M of PAVmed stock for Q2 2023, up 0.66% quarter-over-quarter.
- 3 funds opened new PAVmed positions in Q2 2023 and 6 closed out, a net change of -3 holders.
- The largest PAVmed buyer in Q2 2023 was Charles Schwab, an estimated $35.4K added.
- The largest PAVmed seller in Q2 2023 was Verition Fund Management, an estimated $122K sold.
Based on aggregated 13F filings for Q2 2023.